Ascletis Launches Phase I Studies for Groundbreaking Obesity Treatments in the U.S.

Ascletis Pharma Launches Phase I Trials for Obesity Treatments

Ascletis Pharma Inc., a biotechnology firm based in Hong Kong, has announced the commencement of two important Phase I clinical studies in the United States aimed at addressing obesity. Utilizing cutting-edge science and technology, these trials will evaluate ASC36, an amylin receptor peptide agonist provided through a once-monthly injection, and ASC36_35FDC, a fixed-dose combination therapy that combines ASC36 with a GLP-1R/GIPR peptide agonist named ASC35.

Study Insights

The trials follow the recent clearance of Investigational New Drug (IND) applications by the U.S. Food and Drug Administration (FDA). The ASC36_35FDC Phase I study is structured as a randomized, double-blind, placebo-controlled trial. It is designed to assess the safety, tolerance, pharmacokinetics, and pharmacodynamics of the combination injection among participants with obesity (BMI ≥ 30) or overweight individuals (BMI ≥ 27) who also suffer from weight-related health issues.

The study will involve a total of 176 participants split into two groups; both groups will evaluate different formulations of Injection A and B, each consisting of the two innovative peptide agonists.

Similarly, the ASC36 trial will encompass 144 participants and follows the same rigorous testing framework to ensure both reliability and safety. This urgent focus on obesity treatment is essential given the high prevalence of related comorbidities affecting millions.

Comparative Advantages Over Existing Treatments

Current weight loss treatments require multiple injections per week, such as the combination of eloralintide and tirzepatide, which could mean patients endure up to eight injections each month. In contrast, Ascletis’s once-monthly injection plan for ASC36 and ASC36_35FDC presents a less invasive yet potentially more effective alternative. Data indicate that ASC36_35FDC could offer a significantly greater average relative weight reduction compared to existing treatments, showing promising results in preclinical trials.

Advanced Technology Behind Development

Both injectable therapies have been developed in-house utilizing Ascletis's innovative technologies. They incorporate the company's proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery method and the Ultra-Long-Acting Platform (ULAP), which create self-assembling lipid depot formulations. These formulations are being touted for their excellent stability and efficiency in drug delivery.

The ASC36 solutions are made from low-viscosity lipids and biocompatible solvents, allowing for easy administration via a thin needle. Post-injection, the solution forms a gel-like depot within the subcutaneous tissue, gradually releasing the active pharmaceutical ingredients over extended periods.

Future Prospects

These initial studies mark a significant step forward for Ascletis in the battle against obesity, which affects a large segment of the population and is linked to various health complications. According to Jinzi Jason Wu, Founder and CEO of Ascletis, the company’s ongoing advances paint an optimistic picture for the future of obesity treatments. Moreover, Ascletis plans to escalate its efforts with upcoming Phase III programs for its oral GLP-1 therapeutics, further solidifying its position as a leader at the forefront of the biotechnology sector.

With promising results emerging from laboratory tests and advanced research techniques, the clinical trials for ASC36 and ASC36_35FDC are closely watched by both the medical community and prospective patients eager for effective treatments for obesity.

For more information about Ascletis’s groundbreaking obesity treatments and their commitment to innovative healthcare solutions, visit Ascletis's official website.